Analytics24
19 October
S&P7,659.4−1.11%16 Oct
Nasdaq29,187.6−2.53%16 OctStoxx6,204.2+0.58%16 OctFTSE10,796.3−0.79%Nikkei64,916.7−0.62%Hang Seng24,186.8+0.52%16 Oct10Y5.10%+1 bp16 OctS&P7,659.4−1.11%16 OctNasdaq29,187.6−2.53%16 OctStoxx6,204.2+0.58%16 OctFTSE10,796.3−0.79%Nikkei64,916.7−0.62%Hang Seng24,186.8+0.52%16 Oct10Y5.10%+1 bp16 OctS&P7,659.4−1.11%16 Oct
Markets
The Claims · Open · 553 sessions to 31 Dec · Lilly sold 4,928 million of Zepbound in June against 98 million of Foundayo

VANQUISH names a primary read

Viking Therapeutics reports a primary weight-loss endpoint read from VANQUISH-1 or VANQUISH-2 in a public release before 31 Dec 2028.

XLinkedInEmail
Resolves by
31 Dec 2028
Confirm
The molecule trade got a number.
Kill
The trial stayed blind while the aisle moved.
Grade

Open. Grades from the stated sources when the window ends.

Related writing

← The Claims